NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis $2.10 +0.12 (+6.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.98▼$2.1250-Day Range$1.83▼$2.7752-Week Range$0.80▼$6.28Volume1.08 million shsAverage Volume1.90 million shsMarket Capitalization$256.96 millionP/E RatioN/ADividend YieldN/APrice Target$6.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Mersana Therapeutics alerts: Email Address Mersana Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside199.3% Upside$6.29 Price TargetShort InterestBearish7.82% of Shares Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment1.25Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.91 out of 5 starsMedical Sector221st out of 936 stocksPharmaceutical Preparations Industry95th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMersana Therapeutics has received no research coverage in the past 90 days.Read more about Mersana Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.82% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 1.14%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMersana Therapeutics has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mersana Therapeutics is -0.69. Previous Next 2.9 News and Social Media Coverage News SentimentMersana Therapeutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.80% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mersana Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 6.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mersana Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Mersana Therapeutics Stock (NASDAQ:MRSN)Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Read More MRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRSN Stock News HeadlinesMay 22, 2024 | globenewswire.comMersana Therapeutics to Present at Upcoming Investor ConferencesMay 15, 2024 | seekingalpha.comMersana Therapeutics: On Hold While Waiting For Any Positive NewsJuly 27, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 12, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 10, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comMersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed AnalysisMay 9, 2024 | investorplace.comMRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsJuly 27, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 9, 2024 | globenewswire.comMersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 3, 2024 | globenewswire.comMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comMersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024April 20, 2024 | seekingalpha.comMRSN Mersana Therapeutics, Inc.April 5, 2024 | morningstar.comMersana Therapeutics Inc MRSNApril 4, 2024 | globenewswire.comMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 ExpertsMarch 1, 2024 | seekingalpha.comMersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | nasdaq.comGuggenheim Upgrades Mersana Therapeutics (MRSN)See More Headlines Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$6.29 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+199.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-171,670,000.00 Net Margins-352.01% Pretax Margin-352.01% Return on Equity-260.65% Return on Assets-54.01% Debt Debt-to-Equity Ratio0.72 Current Ratio3.51 Quick Ratio3.51 Sales & Book Value Annual Sales$36.85 million Price / Sales6.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book6.77Miscellaneous Outstanding Shares122,360,000Free Float107,922,000Market Cap$256.96 million OptionableOptionable Beta1.54 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Martin H. Huber M.D. (Age 63)President, CEO & Director Comp: $44kMr. Brian C. DeSchuytner (Age 45)Senior VP, CFO & COO Comp: $626.32kDr. Timothy B. Lowinger Ph.D. (Age 60)Senior VP and Chief Science & Technology Officer Comp: $666.3kMs. Alejandra Veronica Carvajal J.D. (Age 50)Senior VP, Secretary & Chief Legal Officer Comp: $606.51kMr. Mikhail Papisov Ph.D.Co-FounderMr. Ashish Mandelia (Age 49)VP, Controller & Chief Accounting Officer Mr. Jason FredetteSenior Vice President of Investor Relations & Corporate CommunicationsMr. Chuck MillerSenior Vice President of Regulatory AffairsMr. Marc DamelinExe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.Dr. Tushar Misra Ph.D. (Age 63)Senior VP & Chief Manufacturing Officer Comp: $485.89kMore ExecutivesKey CompetitorsBicycle TherapeuticsNASDAQ:BCYCAnaptysBioNASDAQ:ANABCentessa PharmaceuticalsNASDAQ:CNTACronos GroupNASDAQ:CRONMesoblastNASDAQ:MESOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 74,092 shares on 7/26/2024Ownership: 0.370%SG Americas Securities LLCBought 105,209 shares on 7/12/2024Ownership: 0.113%Walleye Trading LLCBought 31,526 shares on 5/17/2024Ownership: 0.026%Jacobs Levy Equity Management Inc.Sold 120,728 shares on 5/16/2024Ownership: 0.662%California State Teachers Retirement SystemSold 7,104 shares on 5/16/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions MRSN Stock Analysis - Frequently Asked Questions How have MRSN shares performed this year? Mersana Therapeutics' stock was trading at $2.32 at the beginning of 2024. Since then, MRSN stock has decreased by 9.5% and is now trading at $2.10. View the best growth stocks for 2024 here. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The firm's revenue for the quarter was up 18.5% compared to the same quarter last year. What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.37%) and SG Americas Securities LLC (0.11%). Insiders that own company stock include Andrew A F Hack, Anna Protopapas, Brian Deschuytner, Arvin Yang, Ashish Mandelia, Alejandra Carvajal, Tushar Misra, Mohan Bala and Timothy B Lowinger. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL) and Inovio Pharmaceuticals (INO). This page (NASDAQ:MRSN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRSN Stock Alerts